U.S. Patent No. 9,943,491 B2 issued on April 17, 2018, for “Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders” It was issued to applicant Echo Pharmaceuticals B.V., of Weesp, Netherlands, and inventors Jan Albert De Vries, Maria Vanesa Fernandez Cid, Ana Maria …
Category: Cannabis IP
CannabIP: U.S. Patent No. 9,962,340 B2
U.S. Patent No. 9,962,340 B2 issued on May 8, 2018, for “Device and method for the transdermal delivery of cannabidiol.” It was issued to applicant Medipatch Inc., of San Diego, California, and inventors Ludwig J. Weimann, of San Diego, California. The assignee is Life Tech Global, LLC, of Irvine, California. The specification discloses a drug …
CannabIP: U.S. Patent No. 9,938,663 B2
U.S. Patent No. 9,938,663 B2 issued on April 10, 2018, for “Methods for Producing Raw Materials from Plant Biomass,” to applicant 9Fiber, Inc., of Silver Spring, Maryland, and inventor Adam Powars, of Denver, Colorado. The claims are directed to a new method for recycling raw plant materials. The specific method is decortication, degumming, decontamination, whitening, …
CannabIP: U.S. Patent No. 9,937,147 B2
U.S. Patent No. 9,937,147 B2 issued on April 10, 2018, for “Edible Base Product Composition,” to applicant NBDD, Inc., and inventor Doug DeGeeter, of San Francisco, California. The claims are directed to an edible product containing concentrates of starch, specifically rice, lipid, specifically tapioca maltodextrin, and at least 33% by weight a concentrate containing a …
CannabIP: FDA Approves First Drug with CBD Active Ingredient
On June 25, 2018, the Food & Drug Administration (FDA) issued a press release in which it approved EPIDIOLEX® for treatment of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome. Lennox-Gastaut syndrome (LGS) is specific type of epilepsy characterized by multiple seizures and affects intellectual development in children. Dravet syndrome is a severe form of epilepsy, a …
CannabIP: U.S. Patent No. 9,901,607 B2
U.S. Patent No. 9,901,607 B2 issued on February 27, 2018, to Mark J. Silen, directed to compositions and method of manufacture of preparing and manufacturing smokeless controlled release of cannabinoids. The specification describes an oral composition including from the cannabis plant material and an additive solution. The cannabis plant material can include any strain from …
CannabIP: U.S. Patent No. 9,894,936 B2
U.S. Patent No. 9,894,936 B2 issued on February 20, 2018, for “Zoned Vaporizer,” to Mark Krietzman. The claims are directed to vape apparatuses, one a full system and the other a portable device. Independent claim 1 recites a system including a controller, heating chamber, lid, intake, and power supply which can control the vape. Independent …
CannabIP: U.S. Patent No. 9,889,100 B2
U.S. Patent No. 9,889,100 B2 issued on February 13, 2018, for “Cannabidiol for Treatment of Severe and Refractory Graft-Versus-Host Disease.” The inventor is Moshe Yeshurun, and the applicant/assignee is Mor Research Applications Ltd., of Tel Aviv, Israel. Mor Research is the patenting and licensing division of Clalit Health Services, the largest of four state-mandated HMOs …
CannabIP: U.S. Patent No. 9,895,342 B2
U.S. Patent No. 9,895,342 B2 issued on February 20, 2018, for “Cannabinoids for Use in the Treatment of Neuropathic Pain.” It is assigned to GW Pharma Ltd., which is a fairly large pharmaceutical company based in the United Kingdom. The invention disclosure relates to methods for treatment of neuropathic pain using cannabinoids, and specifically in …
CannabIP: U.S. Patent No. 9,895,404 B1
U.S. Patent No. 9,895,404 B1 issued on February 20, 2018, for “Cannabidiol Extraction Plant and Processes,” to Paul T. Baskis. This is a utility patent, specified in 35 U.S.C. §101, because it describes a new process for extracting CBD from the cannabis plant.[1] There is certainly a method, or process or algorithm, being described in …